Arbutus Biopharma Corpora... (ABUS)
3.44
0.05 (1.47%)
At close: Feb 20, 2025, 3:59 PM
3.43
-0.44%
After-hours: Feb 20, 2025, 06:37 PM EST
undefined% (undefined)
| Bid | 3.41 |
| Market Cap | 652.80M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.43 |
| PE Ratio (ttm) | -8.01 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.46 |
| Volume | 423,271 |
| Avg. Volume (20D) | 776,769 |
| Open | 3.38 |
| Previous Close | 3.39 |
| Day's Range | 3.37 - 3.45 |
| 52-Week Range | 2.30 - 4.72 |
| Beta | undefined |
About ABUS
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel ...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 26, 2007
Employees 73
Stock Exchange NASDAQ
Ticker Symbol ABUS
Website https://www.arbutusbio.com
Analyst Forecast
According to 4 analyst ratings, the average rating for ABUS stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 45.14% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Arbutus Biopharma Corporation is scheduled to release its earnings on Mar 3, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+0.28%
Barinthus Biotherapeutics shares are trading lower...
Unlock content with
Pro Subscription
10 months ago
+15.87%
Arbutus Biopharma shares are trading higher amid circulation of documents from an Arbutus/Genevant vs Moderna patent infringement lawsuit.
